{"id":"cq-and-pq-starting-on-day-42","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, vomiting, abdominal pain)"},{"rate":"5-15","effect":"Headache"},{"rate":"variable","effect":"Hemolytic anemia (PQ, especially in G6PD deficiency)"},{"rate":"5-10","effect":"Pruritus"},{"rate":"5-10","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chloroquine accumulates in parasite food vacuoles and inhibits heme polymerization, disrupting DNA replication and causing parasite death. Primaquine is a prodrug metabolized to active metabolites that generate reactive oxygen species, particularly effective against the dormant liver stage (hypnozoites) of P. vivax and P. ovale, preventing relapse infections. The combination targets both blood and tissue stages of malaria parasites.","oneSentence":"CQ (chloroquine) and PQ (primaquine) are antimalarial agents that inhibit parasite DNA replication and metabolism, with PQ also targeting hypnozoites to prevent relapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:57.498Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria (Plasmodium vivax and Plasmodium ovale with relapse prevention)"},{"name":"Uncomplicated malaria treatment and relapse prophylaxis"}]},"trialDetails":[{"nctId":"NCT03208907","phase":"PHASE3","title":"DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil","status":"COMPLETED","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2018-07-05","conditions":"Malaria, Vivax, Therapeutics","enrollment":419}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard treatment with no potential synergy"],"phase":"phase_3","status":"active","brandName":"CQ and PQ starting on Day 42","genericName":"CQ and PQ starting on Day 42","companyName":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","companyId":"funda-o-de-medicina-tropical-dr-heitor-vieira-dourado","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CQ (chloroquine) and PQ (primaquine) are antimalarial agents that inhibit parasite DNA replication and metabolism, with PQ also targeting hypnozoites to prevent relapse. Used for Malaria (Plasmodium vivax and Plasmodium ovale with relapse prevention), Uncomplicated malaria treatment and relapse prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}